top of page
Tanya Wragg
Apr 191 min read
Selectively depleting the energy of cancer cells: A new therapeutic paradigm
Over the past fifty years the somatic mutation theory of cancer has emerged as the most successful explanation of the molecular phenotype...
15 views0 comments
hilmarwarenius
Jun 12, 20231 min read
ESSENTIAL MOLECULAR
The essential molecular requirements for the transformation of normal cells into established cancer cells, with implications for a novel...
39 views0 comments
hilmarwarenius
Jun 12, 20231 min read
FURTHER NEWS FOR SYNTHERIX
March 4th 2023 Hilmar Warenius’ Patent on new lead agent ONKONEK filed by SYNTHERIX June 7TH 2023 Peer reviewed new hypothesis about how...
24 views0 comments
-
Mar 13, 20231 min read
TECHNOLOGY DEVELOPMENT
Reaction Biology GmbH will collaborate in developiment of a specific PKM2 assay for ONKONEK activity in human cancers.
13 views0 comments
-
Mar 13, 20231 min read
PATENT NEWS
GB2582571A describing SYNTHERIX unique Coumarin / Naphthalene/ Arginine warhead is at present in PCT in Europe and the USA. A new patent...
23 views0 comments
bottom of page